早期FDG-PET预测转移性乳腺癌初始治疗后的结局
IMPACT-MBC多中心非随机临床队列试验纳入200例新诊断非快速进展转移性乳腺癌患者,在开始一线全身治疗前进行基线活检和FDG-PET/CT,治疗2周后早期FDG-PET,8周后CT疗效评估。早期FDG-PET非进展对8周CT非进展的阴性预测值为94.7%,且能区分长期生存结局,提示早期FDG-PET可改善标准CT评估的结局预测。
要点
- 早期FDG-PET非进展对8周CT非进展的阴性预测值为94.7%。
- 早期FDG-PET非进展者中位PFS 19.4个月、OS 39.4个月。
- 8周CT非进展但早期FDG-PET进展者PFS和OS仍较差。
核心结论
- 在新诊断非快速进展转移性乳腺癌开始一线全身治疗前,治疗2周后早期FDG-PET可识别具有不同长期结局的患者。
- 将早期FDG-PET纳入可改善标准CT评估的结局预测。
研究设计与样本
- 多中心非随机临床队列试验IMPACT-MBC,2013年8月至2018年5月入组新诊断非快速进展转移性乳腺癌患者,共分析200例。
- 基线评估包括转移灶活检、FDG-PET和CT,治疗2周后早期FDG-PET,8周后CT疗效评估。
主要发现
- 早期FDG-PET非进展对8周CT非进展的阴性预测值为94.7%(95% CI, 89.5%-97.4%),在各MBC亚型和仅骨病患者中相似。
- 接受标准治疗且早期FDG-PET非进展者(n=133)中位PFS为19.4个月(95% CI, 15.2-22.8),OS为39.4个月(95% CI, 33.7-48.3)。
- 8周CT非进展但早期FDG-PET进展者中位PFS为9.5个月(IQR, 4.1-18.1),OS为19.4个月(IQR, 8.7-33.0);无早期FDG-PET进展者中位PFS为22.3个月(IQR, 15.3-96.1),OS为40.1个月(IQR, 23.4-72.7)。
关键数值与推荐
- 临床效用定义为早期FDG-PET预测8周CT进展、PFS和OS的能力。
- 主要结局指标为8周进展、PFS和OS。
临床怎么用
- 对于新诊断非快速进展转移性乳腺癌患者,可考虑在治疗2周后行早期FDG-PET辅助识别可能预后不良者。
- 早期FDG-PET非进展对8周CT非进展有较高阴性预测价值,但需结合标准评估综合判断。
局限性
- 为非随机临床队列试验,早期FDG-PET与标准治疗比较并非随机分组。
- 研究纳入非快速进展的新诊断转移性乳腺癌患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Optimizing treatment decisions in metastatic breast cancer (MBC) can alleviate patients' burden and improve quality of life. Whether 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) can be used to better estimate outcomes is unknown. OBJECTIVE: To evaluate clinical utility of early metabolic change on FDG-PET for improving outcome estimation compared with standard diagnostic evaluation in patients with newly diagnosed MBC. DESIGN, SETTING, AND PARTICIPANTS: The multicenter IMPACT-MBC clinical cohort trial enrolled patients with nonrapidly progressive, newly diagnosed MBC from August 2013 to May 2018, before initiation of first-line systemic therapy. Baseline assessment included metastasis biopsy procedure and FDG-PET and CT imaging. Early FDG-PET was performed after 2 weeks of treatment, and CT response evaluation after 8 weeks. Clinical utility was defined as the ability of early FDG-PET to estimate progressive disease (PD) on CT, progression-free survival (PFS), and overall survival (OS). Data were analyzed from October 19, 2025, to February 13, 2026. INTERVENTION: Early FDG-PET or standard-of-care (SOC) biopsy-based treatment. MAIN OUTCOMES AND MEASURES: Clinical utility of molecular imaging to improve outcome estimation of standard diagnostics defined as the capacity to identify poor patient outcomes. Measures were PD at 8 weeks, PFS, and OS. RESULTS: The analysis included 200 patients (median [range] age, 61 [32-84] years; 198 females [99%] and 2 males [1%]). Non-PD on early FDG-PET had a negative predictive value (NPV) of 94.7% (95% CI, 89.5%-97.4%) for non-PD on 8-week CT. This was similar in all MBC subtypes and bone-only disease. Patients with SOC treatment and non-PD on early FDG-PET (n = 133) had a median PFS of 19.4 (95% CI, 15.2-22.8) months and OS of 39.4 (95% CI, 33.7-48.3) months compared to 4.1 (95% CI, 3.3-15.5) months and 18.5 (95% 3 CI, 7.0-33.0) months, respectively (P < .001 for both). Patients with non-PD on 8-week CT but with PD on early FDG-PET had a median (IQR) PFS and OS of 9.5 (4.1-18.1) and 19.4 (8.7-33.0) months compared to 22.3 (15.3-96.1) months and 40.1 (23.4-72.7) months without PD. CONCLUSIONS AND RELEVANCE: In this clinical cohort trial of patients with nonrapidly progressive, newly diagnosed MBC before initiation of first-line systemic therapy, early FDG-PET after only 2 weeks of treatment identified patients with MBC with distinct long-term outcomes. Incorporating early FDG-PET can improve outcome estimation of standard CT assessment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01957332.
引用
- van Geel JJL, Eisses B, Elias SG, et al. 18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial. JAMA Oncol. 2026. PMID: 41989806. doi:10.1001/jamaoncol.2026.0767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。